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Abstract
The protein arginine methyltransferase (PRMT) family of enzymes comprises nine family 
members in mammals. They catalyze arginine methylation, either monomethylation or symmetric/
asymmetric dimethylation of histone and non-histone proteins. PRMT methylation of its substrate 
proteins modulates cellular processes such as signal transduction, transcription, and mRNA 
splicing. Recent studies have linked overexpression of PRMT5, a member of PRMT superfamily, 
to oncogenesis, making it a potential target for cancer therapy. In this study, we developed a highly 
sensitive (Z’ score = 0.7) robotic high throughput screen (HTS) platform to discover small 
molecule inhibitors of PRMT5 by adapting the AlphaLISA™ technology. Using biotinylated 
histone H4 as a substrate, S-adenosyl-l-methionine as a methyl donor, PRMT5 symmetrically 
dimethylated H4 at arginine (R) 3. Highly specific Acceptor beads for symmetrically dimethylated 
H4R3 and streptavidin-coated Donor beads bound the substrate, emitting signal that is 
proportional to the methyltransferase activity. Using this powerful approach, we identified specific 
PRMT5 inhibitors 1608K04 and P1618J22, and further validated their efficacy and specificity for 
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inhibiting PRMT5. Importantly, these two compounds exhibited much more potent efficacy than 
the commercial PRMT5 inhibitor EPZ015666 in both pancreatic and colorectal cancer cells. 
Overall, our work highlights a novel, powerful, and sensitive approach to identify specific PRMT5 
inhibitors. The general principle of this HTS screening method can be applied not only to PRMT5 
and the PRMT superfamily, but may also be extended to other epigenetic targets. This approach 
allows us to identify compounds that inhibit the activity of their respective targets, and screening 
hits like 1608K04 and P1618J22 may serve as basis for novel drug development to treat cancer 
and/or other diseases.
Graphical abstract
Proposed workflow of drug development pipeline with adapted AlphaLISA HTS-based screen to 
discover inhibitors of epigenetic targets like PRMT5 with possible significance in disease 
treatment.
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1. Introduction
Protein arginine methyltransferases (PRMTs) catalyze the transfer of methyl groups from S-
adenosylmethionine (SAM or AdoMet) to guanidino nitrogen of arginine on its substrate 
protein, resulting in methylated arginine. This posttranslational modification occurs on both 
histones and non-histone proteins, thereby affecting cellular function and development. 
Mammalian PRMTs are divided into three groups based on their symmetric or asymmetric 
arginine methylation pattern: type I PRMTs catalyze the formation of x-NG-
monomethylarginine (MMA) and asymmetric x-NG, NG-dimethylarginine (aDMA); type II 
PRMTs catalyze the formation of MMA and symmetric x-NG, N0G-dimethylarginine 
(sDMA), and type III PRMTs bring about only monomethylation. Type I PRMTs include 
PRMT1, 2, 3, 4, 6, and 8, while PRMT5 and 9 are Type II PRMTs. PRMT7 is classified as a 
type III PRMT.1, 2
Methylation of proteins by PRMTs is involved in a variety of cellular functions related to 
signal transduction, transcription, DNA repair, and mRNA splicing. Interestingly, recent 
studies have linked overexpression of these enzymes to a wide variety of cancers.3 Both 
PRMT1 and PRMT2 have been implicated in epithelial-mesenchymal transition (EMT) in 
breast cancer cells.4,5 PRMT1 and 6 dysregulations were shown to promote growth of 
bladder and lung cancer cells.6 Our lab was the first to demonstrate that PRMT5 activates 
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nuclear factor kappa B (NF-κB) by symmetrically dimethylating the p65 subunit of NF-κB 
at R30.7 Furthermore, PRMT5 is upregulated in several types of cancers including breast, 
cervix, liver, colon, lung, ovary, bladder, and particularly in pancreatic cancers.7 - 9 Thus, the 
PRMT family has been widely implicated in cancer development. Since PRMT5 has 
generated a lot of interest as a potential oncogene in a wide variety of cancers, in this study, 
we decided to use PRMT5 as the representative PRMT family member as the target for 
assay development to screen for small molecule inhibitors.
High throughput screening (HTS) techniques can be used to effectively screen for small 
molecule inhibitors against specific targets. The inhibitors identified using HTS not only 
serve as invaluable tools to study important targets in cancer such as PRMT5, but also 
provide prospective candidates for therapeutic development. An ideal HTS screen is 
reproducible, sensitive, scalable, cost-efficient, and most importantly, effective. In this study, 
we have adapted the AlphaLISA™ technique, a bead-based Amplified Luminescent 
Proximity Homogeneous Assay-Linked ImmunoSorbent Assay that satisfies the criteria for 
an effective HTS approach. Compared to conventional methods like time-resolved 
fluorescence energy transfer (TR-FRET) assays and enzyme-based assays, the AlphaLISA 
technology has been proven to have better sensitivity, less variability, and to possess the 
ability to be automated for large-scale reactions. Additionally, since it is a non-radioactive, 
proximity-based assay, the hassles and dangers of radioactivity-based approaches can be 
avoided. Overall, AlphaLISA provides a highly sensitive and scalable approach to perform 
assay development for an HTS.
We adapted the AlphaLISA technology to develop an effective assay to screen for small 
molecule inhibitors of PRMT5 (Fig. 1). Symmetric dimethylation of its substrate by PRMT5 
brings the AlphaLISA beads in close proximity and a greatly amplified signal can be 
produced. Upon excitation with 680nm of light, a photosensitizer component in the “Donor” 
bead converts ambient oxygen to an excited singlet state. The singlet oxygen molecules react 
with a thioxene derivative in the “Acceptor” bead, emitting light at 370nm that further 
activates a fluorophore contained in the Acceptor bead itself. The Acceptor beads have a 
specific antibody tag that recognizes the symmetrically dimethylated PRMT5 substrate. The 
fluorophore on the Acceptor bead subsequently emits light at 615nm, which can be 
quantified using an EnVision® reader. If the specific dimethylation tag is absent, the singlet 
oxygen molecules produced upon the Donor bead excitation will not be transferred to the 
Acceptor bead, as proximity of the Acceptor bead will not occur in the absence of this 
specific interaction. As a result, a very low background signal would be produced. This 
guarantees the specificity of the signal produced and thereby accurate quantification of the 
methyltransferase activity.
In this paper, we describe the AlphaLISA assay development to the HTS stage with a robust 
signal to background (S/B) ratio, adapting a PRMT5-specific protocol, such that the 
efficiency of this approach in an HTS setting is optimized. As a proof-of-principle, we 
highlight two hits (P1608K04 and P1618J22) from our screening that showed significant 
inhibition of PRMT5 methyltransferase activity. These hits were identified by screening 
small molecule compound libraries that contained natural as well as synthetic compounds, 
and compounds with known pharmacological activity. We confirmed their PRMT5-specific 
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activity using a concentration-dependent AlphaLISA assay and tested the in vitro efficacy by 
checking their effect on viability of a panel of PRMT5-overexpressing pancreatic ductal 
adenocarcinoma (PDAC) and colorectal cancer (CRC) cell lines. Further evidence for 
specificity of these inhibitors was demonstrated by the reduction in methylation of the p65 
subunit of NF-κB, subsequent decrease of NF-κB activity, and the reduced expression of 
NF-κB target genes. Importantly, comparing with previously published data from our lab8 
with regards to a commercially available PRMT5 inhibitor EPZ015666,10 we observed 
much lower IC50s of P1608K04 and P1618J22 than that of EPZ015666 in both PDAC and 
CRC cells, confirming both the great advantage of the AlphaLISA HTS technique that we 
adapted and the considerable promise that P1608K04 and P1618J22 hold for further drug 
development.
Overall, this study illustrates a systematic approach to design, optimize and execute a HTS 
approach for targets of interest such as PRMT5 using AlphaLISA. This study is significant 
as it describes a highly effective (Z’ factor=0.7) HTS system to screen for PRMT5 inhibitors 
with a robotic system. Importantly, it can serve as a template for other studies involving 
small molecule inhibitors for other epigenetic enzymes. Guided protocol development based 
on this study will allow researchers to follow similar considerations and develop HTS 
screening protocols to achieve their scientific goals. Notably, we identified two novel 
PRMT5 small molecule inhibitors that are more potent than the commercial inhibitor 
EPZ015666 in PDAC and CRC cells. In the broader sense, compounds identified in such 
HTS studies are critical tools to study the underlying mechanism of the targets of interest in 
disease models, thus, may serve as basis for novel drug development in the future.
2. Materials and methods
2.1 Reagents and peptides
The methyl group donor SAM was purchased from New England Biolabs (Ipswich, MA). 
Unmethylated biotinylated histone H4 peptide substrate at arginine (R) 3 (unmeH4R3) was 
obtained from AnaSpec (Fremont, CA). The 23-amino acid sequence of H4R3 peptide was 
as follows: SGRGKGGKGLGKGGAKRHRKVLRGG-K(biotin)-NH2, with the third 
arginine site available for dimethylation as per the assay protocol. For screening, dimethyl 
sulfoxide (DMSO) stock of library compounds comprising of approximately 10,000 pure 
natural products, semi-synthetic natural products and reported bioactives were purchased 
from Analyticon Discovery (Rockville, MD), MilliporeSigma (St. Louis, MO) and 
Microsource Discovery Systems Inc (Gaylordsville, CT). The compound libraries were 
stored at −80°C. Anti-methyl-H4R3 AlphaLISA beads, Streptavidin-tagged Donor beads, 1× 
Epigenetics buffer, TopSeal™-A film, OptiPlate™-384 white opaque plates, and EnVision® 
Multilabel Reader were obtained from PerkinElmer (Waltham, MA).
2.2 Cell lines
PDAC cell lines (PANC1, MiaPaCa2 and AsPC1) were kindly provided by Dr. Murray Korc 
(Indiana University School of Medicine). CRC cell lines (HT29, HCT116, and DLD1) were 
purchased from American Type Culture Collection (ATCC). PANC1 and MiaPaCa2 cell 
lines were grown in HyClone™ Dulbecco’s Modified Eagle Medium (DMEM) (GE 
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Healthcare, Logan, UT), with addition of 1% of penicillin/streptomycin and 5% fetal bovine 
serum (FBS). CRC cells were maintained in HyClone™ Roswell Park Memorial Institute 
Medium (RPMI 1640) (GE Healthcare, Logan, UT), with 1% penicillin/streptomycin and 
5% FBS. 293 cells overexpressing Flag-PRMT5 were generated as described previously7 
and cultured in HyClone™ DMEM with 1% penicillin/streptomycin and 5% FBS. The cells 
were grown at 37°C and 5% CO2 conditions. Authentication of cell lines was carried out 
using 9Marker STR Profile.
2.3 Enzyme purification
Flag-tagged PRMT5 enzyme was purified from 293 cells overexpressing Flag-PRMT5 by 
co-immunoprecipitating with Flag beads from MilliporeSigma (St. Louis, MO). 293-Flag-
PRMT5 cells were cultured in 15cm plates, ~90% confluence per plate. After washing the 
cells with 1× phosphate buffered saline (PBS), the cells were spun down at 1,200rpm for 10 
min at 4°C. The pellets were lysed by adding lysis buffer (50mM Tris-HCl, pH7.4, 150mM 
NaCl, 1mM EDTA, 100nM Phenylmethanesulfonyl fluoride, 0.5M Na3NO4, 1% Triton 
X-100 and protease inhibitor tablets) and vortexing 4-5 times over a period of 20 min. The 
lysed cells were spun at 3,400rpm for 30 min, and the supernatant was transferred to the 
prewashed Flag beads suspended in 1× cold PBS. The lysed cells/beads mixture was rotated 
at 4°C. After overnight incubation, the beads were spun down and washed 4 times using 1× 
wash buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 1mM EDTA, 0.5% Triton X-100). 
Post-washing, the beads were mixed with Flag peptide and rotated for 1 h at 4°C, then spun 
down. Supernatant (the PRMT5 enzyme product) was added with storage buffer (40mM 
Tris, 110mM NaCl, 2.2mM KCl, 3mM Dithiothreitol (DTT), 20% glycerol), and used 
immediately for the AlphaLISA assay or aliquoted at −80°C until further use.
2.4 AlphaLISA-based H4R3me2 detection assay
The AlphaLISA reaction was run in 384-well white opaque plates with a total reaction 
volume of 30μl. All the parameters of the assay were determined using standardized 
conditions by testing 10-100nM of unmeH4R3 and of 0.2-4000μM SAM. In the pilot 
experiments as well as the Z’ test, the following protocol was used: the biotinylated 
unmeH4R3 substrate stock as well as the SAM stock was diluted using milliQ water with 
final concentrations of 30nM and 100nM respectively in the reaction well. The PRMT5 
enzyme prep was diluted at 1:10 ratio in Assay buffer (30mM Tris, pH 8.0, 1mM DTT, 
0.01% Bovine serum albumin, 0.01% Tween-20) before being used. 10μl of 
unmeH4R3:SAM mixture and 10μl of diluted enzyme stock were mixed in each well and 
incubated at R.T. for 1h. Following this, the Acceptor bead stock (with an antibody tag 
specific for H4R3me2) was diluted 1:50 using 1× Epigenetics buffer to a final concentration 
of 20μg/ml. 5μl of the diluted bead stock was dispensed in each of the reaction wells. After 
incubation with the Acceptor beads for 1h at room temperature (R.T.), the streptavidin-
coated Donor bead stock (specific for the biotinylated substrate) was diluted at 1:50 using 1× 
Epigenetics buffer to a final concentration of 20μg/ml, and 5μl was dispensed in each of the 
reaction wells (Table 1). Following incubation with Donor beads for 30 min in the dark, the 
plates were immediately read using the “Alphascreen” filter in the EnVision® Reader. To 
assess background of the reaction in the negative control wells, all the conditions were same 
except 10μl of 1× assay buffer was added instead of enzyme stock.
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2.5 High-throughput screening
For the HTS, we used the optimized protocol as described in Table 1. Briefly, 10μL of the 
substrate 2× mix (60nM unmethylated peptide, 200μM SAM in MilliQ water) was dispensed 
using Multidrop into each well of the assay plates. The final reaction concentration was 
30nM unmeH4R3 peptide and 100μM SAM. Next, 250nL of 1mM DMSO stock of the 
library compounds was transferred to columns 1-20, with a final compound concentration of 
12.5μM and final DMSO of 1.25% in each well. 5% DMSO/water (1% DMSO final) was 
added to column 21-24 to keep the DMSO concentration consistent with the wells in which 
the compounds were added. Next, 10μL enzyme (ten-fold dilution of the enzyme prep in 
assay buffer) was dispensed to columns 1-22 using MultiFlo in each plate. At the same time, 
10μL of the 1× assay buffer was added to columns 23-24 in each plate. Thus, columns 21-22 
serve as positive “maximum signal” controls (no compound, with PRMT5 enzyme added) 
and columns 23-24 act as “background signal” controls (no compound, no enzyme added). 
Columns 1-20 in each plate had the different compounds added, with 1 replicate for each 
compound in the library. The plates were incubated at R.T. for 1h. 5μL anti-H4R3me2 
Acceptor beads (1:50 dilution of the 5mg/mL stock in 1× Epigenetics Buffer) were then 
dispensed using MultiFlo into each well of the assay plates. The plates were incubated at 
R.T. for 1 h. 5μL Donor beads (1:50 dilution of the 5mg/mL stock in 1× Epigenetics Buffer) 
were dispensed using MultiFlo into each well of the assay plates. The plates were incubated 
at R.T. for 30 min followed by Alpha signal reading on EnVision® reader.
2.6 Quenching experiment
In this assay, the incubation and assay conditions were relatively similar to the HTS assay 
described above. The major differences were: (1) histone H4 pre-methylated at arginine 3 
(Biotin-H4R3me2) (AnaSpec, Fremont, CA) was used as a substrate at a final concentration 
of 15nM; (2) No PRMT5 enzyme or unmethylated substrate was included in the experiment, 
and (3) The plate design differed as follows: the first two columns did not have any 
compound (positive control). Columns 1-22 had pre-methylated Biotin-H4R3me2 substrate. 
The last two columns did not have this pre-methylated substrate (negative control; 
background). Diluted AlphaLISA beads (Acceptor and Donor) were added to each well.
2.7 MTT [(3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide)] assay
Cells were seeded at 60% confluence in Corning® Costar® clear flat-bottom 96-well plates 
and increasing concentrations of P1608K04 and P1618J22 were added to the wells 
respectively. After incubation for 4 days, 10μl of MTT dye (Sigma-Aldrich, St. Louis, MO) 
was added directly to each well. The dye was incubated with the cells for 2 h at 37°C. The 
media was then aspirated and 10μl of DMSO was then added to each well. The colorimetric 
dye was quantified using Synergy H1 Multi-Mode Reader from BioTek Instruments Inc. 
(Winooski, VT).
2.8 Western blotting
10% polyacrylamide gel was loaded with protein samples and transferred overnight at 4°C 
to a polyvinylidene fluoride (PVDF) membrane (Thermo Fisher Scientific, Waltham, MA). 
Symmetric demethylation at R30 subunit of p65 was detected by generating a customized 
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polyclonal primary antibody (in collaboration with GenScript Inc. Piscataway, NJ) used at 
1:750 dilution in 5% bovine serum albumin. β-actin was detected using its corresponding 
antibody with 1:5000 dilution in 5% milk (MilliporeSigma, St. Louis, MO). Corresponding 
secondary antibodies were used and the protein signal was detected using enhanced 
chemiluminescent (ECL) detection method (PerkinElmer, Waltham, MA).
2.9 NF-κB Luciferase assay
NF-κB luciferase construct p5XIP10 containing five tandem copies of NF-κB binding site 
from one of its target genes, IP10 was used.7, 8 The p5XIP10 construct was transfected 
transiently in cells using Lipofectamine™ LTX Reagent with PLUS™ Reagent (Thermo 
Fisher Scientific, Waltham, MA). Cells were lysed 48 h post transfection with or without 
PRMT5 small molecule inhibitors treatment. Luciferase activity was measured using the 
Luciferase Assay System with Reporter Lysis Buffer kit (Promega, Madison, WI) by using a 
manufacturer provided protocol and the Synergy H1 Multi-Mode Reader.
2.10 Quantitative PCR
Total RNA was isolated from ~90% confluent plate of cells using Trizol as per previously 
described protocol.7 cDNA was then synthesized using the SuperScript III First-Strand 
Synthesis System (Invitrogen, Carlsbad, CA) by reverse-transcriptase (RT) PCR. Primers for 
the final step were designed using Primer Express 3.0 software and quantitative PCR 
(qPCR) was carried out using the FastStart Universal SYBR Green Master ROX kit (Roche, 
Indianapolis, IN).
2.11 Structural analysis and docking
For docking, chain A of PRMT5 protein in 4×61.pdb from the Protein Data Bank was used. 
All docking experiments were performed by Glide program (version 7.5) of the Schrodinger 
suite in standard precision mode.11–14 Control docking experiment was performed by 
deleting the ligand EPZ015666 from the crystal structure while keeping the ligand SAM and 
could reproduce the binding pose of EPZ015666 seen in the crystal structure. Compounds 
P1608K04 and P1618J22 were docked into the PRMT5 active site under two conditions. In 
one experiment, the compound was docked into the PRMT5 active site in which SAM was 
kept. In the other experiment, compounds were docked into the completely empty active site 
in which SAM was deleted. Figures were prepared with Maestro version 11.2.14
2.12 Statistical analysis
The Z’ factor was calculated using the formula described in Zhang et al.: [Z’ = 1− {3 × SD 
positive control + 3 × SD negative control} / (mean positive control – mean negative 
control}]. Percent inhibition for the compound library was calculated as follows: [({Avg. 
maximum reading – compound reading}/ Avg. maximum reading) × 100].15 Statistical 
software GraphPad Prism (San Diego, CA) was used. The p-values <0.05 were considered 
statistically significant.
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3. Results
3.1 Development and optimization of AlphaLISA protocol
As shown in Fig. 1, AlphaLISA protocol requires several critical components, including 
substrate H4R3, the methyl donor SAM, PRMT5 enzyme as well as Acceptor and Donor 
beads. We purified PRMT5 enzyme using co-immunoprecipitation experiments with Flag 
beads from 293-PRMT5-Flag cells. The manufacturer-recommended dilutions for the 
Acceptor as well as the Donor beads helped us to obtain the desired signal. The major 
optimization was necessary for the unmethylated H4R3 substrate (unmeH4R3) and SAM 
concentrations to be used in the experiment. First, we optimized the substrate concentration 
by running the AlphaLISA assay with 10-100nM final concentration of the unmeH4R3 
substrate in the reaction well. We observed that with increasing concentrations of substrate 
there was a predictable increase in the AlphaLISA signal (Fig. 2A). Since using the lower 
concentrations provided quite a robust signal in the pilot experiment, we decided to use 
30nM of unmeH4R3 to avoid unnecessary use of substrate.
Next, with the aim to maximize the AlphaLISA signal, we determined if a specific 
concentration for methyl donor SAM worked best in this assay. We tested a wide range of 
SAM concentrations (0.2μM to 2000μM) while keeping all the other components same, 
including the substrate concentration at 30nM as described above. We observed a steady 
increase in AlphaLISA signal, with a peak at 100μM SAM, and then decreasing with the 
higher concentrations (Fig. 2B). Thus, we decided to choose a final concentration of 100μM 
SAM in our HTS assay. These assays also allowed us to adjust and test volumes and 
concentrations that were permissible for the robotic approach, thus helping us to automate 
the addition of these reagents in the actual HTS.
3.2 Determination of Z’ factor
After successfully determining the important parameters for assay development, we 
executed the Z’ test to check the robustness of the assay. Calculation of the Z’ factor allows 
for evaluation and validation of HTS assays .15 We used a 384-well white opaque plate to 
run the Z’ test. Briefly, half of the plate was used as “maximum signal” wells (with the 
PRMT5 enzyme added) and the other half was used as “background wells” (with no PRMT5 
enzyme, only assay buffer added). We used a 30μl reaction volume as described in the 
Materials and Methods section. The graph for Z’ factor determination is illustrated in Fig. 3. 
The Z’ factor was calculated to be 0.7 and a signal/background ratio of ~8.3, which is 
indicative of the robustness and reproducibility of the assay. Once the assay was proven 
HTS-compatible, the next step was to scale it up to run a HTS screen using large-scale small 
compound libraries.
3.3 Execution of the HTS screening to identify specific inhibitors of PRMT5 
methyltransferase activity
A major advantage of AlphaLISA technology is the ability to be scaled to a HTS setting 
upon validation. After the Z’ test confirmed the robustness of the assay, we used this assay to 
screen small-molecule compound libraries (as described in the Materials and methods 
sections 2.1 and 2.5) to identify hits with PRMT5 methyltransferase inhibition activity. 384-
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well white opaque plates were used like our pilot experiments for assay development. By 
adapting our pilot AlphaLISA assay to the MultiFlo robotic system to dispense reagents, we 
automated the lengthy process of testing each of the 10,000 compounds and reduced the 
volume of reagents required, as the system could dispense low microliter volumes, thus 
making the overall process time-efficient and cost-effective. Unmethylated histone H4 
substrate:methyl donor SAM were added to all wells of the plate. Each of these wells was 
also added with individual compounds in columns 1-20. An equivalent amount of 
DMSO:water was pipetted into columns 21-24 to equalize the final DMSO concentration 
across all wells in the plate. Enzyme was dispensed to columns 1-22 and 1× assay buffer was 
added to columns 23-24 in each plate. Thus, columns 21-22 served as positive “maximum 
signal” controls (no compound, with PRMT5 enzyme added) and columns 23-24 acted as 
“background signal” controls (no compound, no enzyme added). Acceptor beads, specific 
for the dimethylated H4R3 and Donor beads were dispensed in all the wells.
Several compounds showed the capacity to inhibit PRMT5 methyltransferase activity. These 
hits were ranked based on their percent inhibition values. Next, in order to obtain an even 
more accurate list of positive hits, it was imperative to rule out the false positive hits. To 
achieve this goal, we conducted the Alpha signal quenching experiment. False hits can result 
from interference with the AlphaLISA assay itself rather than inhibiting the enzymatic 
reaction, such as compounds that absorb light at 620 nm or the compounds that absorb 
singlet O2, resulting in quenching of the Alpha signal. One way to eliminate these “Alpha 
signal quenchers” was to screen those compounds in a control assay, in which only histone 
H4 pre-methylated at arginine 3 (Biotin-H4R3me2) was used without adding the PRMT5 
enzyme and running the enzymatic reaction. In this way, the Biotin-H4R3me2 peptide will 
bring the Donor beads and Acceptor beads in close proximity to produce the Alpha signal. 
In this setting, if any compound reduced the Alpha signal, it would be a quencher instead of 
a real inhibitor. This is because this reduction in signal is unrelated to PRMT5 activity which 
itself is absent from this reaction. Fig. 4 illustrates the experimental design and plate layout 
for this filtering experiment among 320 top hits from the HTS screening to eliminate any 
Alpha signal quenchers. The first and last two columns did not contain compounds, but the 
first two columns had the pre-methylated peptide substrate which resulted in a high signal; 
the last two columns did not have me-H4R3 substrate and provided the readings for the 
background signal. Every well of the plate had both the Acceptor and Donor beads. We 
identified 64 potential hits that were not false positives and repeated the AlphaLISA to 
reconfirm their inhibition activity. Several of the top hits identified after this rigorous 
screening process have been illustrated in Fig. 5A, with a cut-off value of over 60% 
inhibition of PRMT5 methyltransferase activity. We conducted preliminary testing using 
concentration-dependent AlphaLISA assay for all these compounds to check the 
corresponding effect on PRMT5 methyltransferase activity. P1608K04 and P1618J22 (Fig. 
5B) showed the most promise. In a confirmation experiment, we observed that increased 
concentrations of both P1608K04 and P1618J22 led to a concurrent decrease in AlphaLISA 
signal with low IC50 values of ~1.5μM and 16.5μM, respectively (Fig. 6A and B). Thus, we 
employed a stepwise filtering protocol for screening ~10,000 compounds using an 
AlphaLISA-based approach, and identified two promising hits that are specific for reducing 
the PRMT5 methyltransferase activity (Fig. 5B).
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3.4 P1608K04 and P1618J22 are potent inhibitors of PRMT5 activity in vitro
In order to test the effectiveness of these promising PRMT5 inhibitors in the context of 
PDAC and CRC, we used the MTT assay with increasing concentrations of P1608K04 and 
P1618J22 in PDAC and CRC cell lines. Both P1608K04 (Fig. 7A and C) and P1618J22 (Fig. 
7B and C) showed great efficacy in decreasing the cell viability in PDAC (PANC1, 
MiaPaCa2, and AsPC1) and CRC cells (HT29, HCT116, and DLD1). Importantly, both 
compounds were much more potent (have lower IC50) than the commercial PRMT5 
inhibitor EPZ015666 in PDAC and CRC cells (Fig. 7C and Supplementary Table 1). 
Therefore, our data suggested that P1608K04 and P1618J22 are powerful PRMT5 inhibitors 
in PDAC and CRC cells. Furthermore, the inhibitors identified using our PRMT5-specific 
AlphaLISA assay could be used as basis for novel drug development and tools to further 
study PRMT5-driven mechanisms in these cancers.
3.5 P1608K04 and P1618J22 inhibited PRMT5-mediated NF-κB methylation, activation and 
target gene expression
A previous study in our lab identified p65 subunit of NF-κB as a novel substrate of PRMT5 
via methylation of its R30 residue.7 To test the specificity of PRMT5 inhibitors, we 
examined their effect on p65 methylation in both PANC1 and HT29 cells. Western analysis 
with a site-specific antibody against dimethylated R30 residue of p65 (Materials and method 
section 2.8) showed decreased R30 methylation on p65 after the treatment of P1608K04 or 
P1618J22 (Fig. 8A and B), confirming that these inhibitors specifically attenuated PRMT5-
mediated NF-κB methylation in these cells.
Since NF-κB R30 methylation leads to its activation,7 we wondered whether P1608K04 and 
P1618J22 may inhibit NF-κB activation and its target gene expression. NF-κB luciferase 
assay was conducted to determine the effect of compound treatment on PRMT5-mediated 
NF-κB activation in PDAC and CRC cells. We confirmed that treatment of P1608K04 and 
P1618J22 for 48 h at the indicated concentrations significantly decreased NF-κB activity in 
both PANC1 (Fig. 9A) and HT29 (Fig. 9B), respectively. It is important to note that it 
requires a much higher concentration of the commercial PRMT5 inhibitor EPZ015666 
(~85-200μM in PANC1, and 200-300μM in HT29 cells)8 to observe a similar effect per our 
previously published data,8 demonstrating that both P1608K04 and P1618J22 are more 
effective than EPZ015666 in decreasing PRMT5-mediated NF-κB activation in PDAC and 
CRC cells.8
In addition to the above evidence, since PRMT5-mediated NF-κB activation leads to the 
induction of well-known cancer-promoting NF-κB target genes, such as interleukin8 (IL8) 
and tumor necrosis α (TNFα) in PDAC and CRC cells,8 we conducted quantitative PCR to 
determine the effect of P1608K04 and P1618J22 on the expression of these two genes. As 
shown in Fig. 9, treatment of PANC1 (Fig. 9C) or CRC (Fig. 9D) cells with these two 
compounds led to significantly decreased expression of both IL8 and TNFα.
Collectively, the above evidence affirmed that P1608K04 and P1618J22 are PRMT5 specific 
inhibitors that function through inhibiting PRMT5-mediated NF-κB methylation, activation, 
and its downstream target gene expression.
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3.6 Predicted structural binding of P1608K04 and P1618J22 to PRMT5
To better understand the potential binding mechanism of P1608K04 and P1618J22 to 
PRMT5, we used a directed computer-based docking approach of these inhibitors to the 
PRMT5 crystal structure. Comparing the crystal structure of commercial PRMT5 inhibitor 
EPZ015666 with the predicted binding poses of the two inhibitors we identified, we 
explored how our inhibitors bind in conjunction with EPZ015666. As illustrated in Fig. 10A 
and B, the best-scoring binding pose for P1608K04 has been depicted in the presence 
(SAM-bound PRMT5) and absence (Apo-PRMT5) of the methyl donor SAM, respectively. 
As shown in Fig. 10A, P1608K04 binds to a similar location to that of EPZ015666 in the 
presence of SAM. Interestingly, in the absence of SAM (Fig. 10B), P1608K04 partially 
occupies the SAM binding site, thereby potentially blocks the SAM-PRMT5 interaction. 
Blocking SAM binding could be a potential avenue through which PRMT5 
methyltransferase activity is affected. Based on the docking scores listed in Fig. 10E, 
P1608K04 is more likely to bind in the absence of SAM.
In the case of P1618J22, we also observed a similar binding pose to that of EPZ015666 in 
the presence of SAM, but a preferential binding to the SAM binding site in the absence of 
SAM (Fig. 10C and D). However, for P1618J22, binding affinities are very close in the 
presence and absence of SAM, thus it is impossible to predict which pose the ligand would 
prefer solely based on structural docking studies.
The ligand affinity maps in Fig. 10F and G illustrate the PRMT5 residues that can 
potentially interact with P1608K04 (Left panels) or P1618J22 (Right panels), in the presence 
(upper panels) or absence (lower panels) of SAM, respectively. Key residues unique to the 
PRMT5 protein, such as Glutamine (E) 444 residue that is part of the catalytic cleft of 
PRMT5 and Phenylalanine (F) 327 critical for PRMT5 product specificity8 are involved in 
the interactions with these inhibitors as well. The interactions also differ from EPZ015666,8 
possibly leading to the different efficacy between them. In the future, it will be interesting to 
explore with the site mutagenesis approach in determining how important these residues and 
others (Fig. 10F and G) are for the binding mechanism of these inhibitors to PRMT5.
Collectively, our data support the hypothetical model (Fig. 11) that inhibitors of PRMT5, 
such as P1608K04 and P1618J22, bind to PRMT5, inhibit PRMT5-mediated NF-κB 
activation and its downstream target gene expression, therefore, resulting in the alleviation of 
cancer phenotype in PDAC and CRC.
4. Discussion
Epigenetic modifications play an important role in normal cellular function and development 
in nearly every aspect of biology, making it one of the most important fields in scientific 
research. Dysregulation of epigenetic modifications leads to serious disruptions of regular 
functioning in humans and is the underlying cause of promoting a wide range of disorders 
including cancers. A plethora of studies have linked overexpression of epigenetic enzymes 
with promotion and metastasis of varied cancers. Thus, a great deal of interest has been 
generated in the field to exploit these epigenetic enzymes as potential therapeutic targets. To 
date, successful attempts at developing inhibitors for epigenetic targets have been made, 
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with the histone deacetylases (HDAC) family being the most prominent example. Vorinostat 
and romidepsin are HDAC inhibitors that are already FDA approved, and many others are 
currently under clinical trials.16 It is imperative to also explore other critical epigenetic 
enzyme families like PRMTs by developing HTS screens and identifying potential inhibitors 
of clinical significance.
Various assays for HTS that have been used in recent times were considered to screen for 
PRMT family member inhibitors. Among the current available technologies, AlphaLISA is 
proved to be an excellent choice for this purpose for various reasons. For instance, in the 
case of radiometric assays, the cost and danger associated with its usage and the generation 
of radioactive waste are a huge deterrent. Enzyme-based assays like ELISA have been quite 
popular for screening in the past. However, with these assays, the scaling-up approach can 
prove to be quite expensive and cumbersome. As the HTS field grows, there is a dire need to 
develop economical and scalable approaches to screen for active compounds against 
potential targets. AlphaLISA is a viable option because it provides a straightforward 
protocol for assay development, and its robustness, sensitivity, cost-effectiveness, and ease 
of use. We conducted extensive troubleshooting and adapted all the loading volumes and 
concentrations to be compatible with a robotic system. A big limitation of the non-robotic 
approach is the cumbersome and expensive nature of the study, with addition of 10,000 
compounds and reagents involved as part of the screening protocol. The ease of automation 
provided by our technique will help to drive high scale screening studies. Additionally, the 
robotic system allows for higher accuracy with its state-of-the-art pipetting system as well as 
cost efficiency as it enables the use of very low volumes of reagents. If using the appropriate 
biotinylated substrate, methyl donor, epigenetic-tag specific Acceptor beads, and 
Streptavidin-coated Donor beads, this assay can be customized for other epigenetic targets 
as well (Fig. 1).
As a prominent member in its superfamily, PRMT5 was chosen as our representative 
enzyme in this screen system. As described in Figs. 2–4, we employed a multi-step approach 
to identify top hits from small compound libraries. We then optimized the assay and tested 
its robustness using the reliable Z’ test, which was determined to be 0.7. Upon completion of 
the screen of libraries containing natural products and biologically active compounds, we 
then sorted through the top hits. Our results indicated that P1608K04 and P1618J22 are the 
most effective PRMT5 inhibitors from our screen. Both compounds demonstrated 
considerable efficacy in concentration-dependent AlphaLISA assays (Fig. 6), and in MTT 
assays in PDAC and CRC cells (Fig. 7), respectively.
The identification of novel PRMT5 inhibitors is of great importance. Several years ago, our 
lab demonstrated that PRMT5 symmetrically dimethylates NF-κB to trigger its activation.7 
Since NF-κB is a pivotal culprit in PDAC and CRC,8 inhibition of PRMT5-mediated NF-κB 
activity can ultimately lead to the impediment of its tumorigenic properties in PDAC and 
CRC.
In this study, we confirmed the significant inhibitory effect of P1608K04 and P1618J22 on 
PRMT5-mediated NF-κB methylation, activation, and its downstream target gene expression 
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(Figs. 8 and 9). Overall, our findings support the specific activity of these inhibitors against 
PRMT5.
To understand how P1608K04 and P1618J22 may bind to PRMT5, we delved deeper into 
the mechanism of the inhibitor-enzyme interaction using structural docking analyses. As 
shown in Fig. 10, we identified specific residues in the binding interaction between these 
two compounds and PRMT5. This analysis suggested that both inhibitors can potentially 
inhibit PRMT5 through certain similar but also varied mechanisms. For instance, both seem 
to bind to residues that intersect with the SAM binding site in the Apo states, suggesting that 
one possible way these inhibitors work is by interfering with SAM binding to its consensus 
site on PRMT5 structure. Ligand affinity map analysis (Fig. 10F and G) suggests that both 
P1608K04 and P1618J22 interact with two key residues (E444 and F327) that are unique to 
the PRMT5 structure,8 also alluding to their specificity. E444 is a key residue in the catalytic 
cleft of PRMT5, while F327 interacts with the substrate and plays an important role in 
determining product specificity of PRMT5.17 Both P1608K04 and P168J22 could contribute 
to PRMT5 inhibition via the interaction with these two key residues. This binding poses of 
P1608K04 and P168J22 are also different from that of EPZ015666, suggesting that there is a 
distinction between our compounds and EPZ015666, and could possibly contribute to the 
different efficacies in inhibiting PRMT5 (Figs. 10A–D). In the future, mutating some of 
these residues can help us locate critical sites on PRMT5 for the inhibitor-enzyme 
interactions and elucidate the mechanism of action of P1608K04 and P1618J22 for PRMT5 
inhibition. Furthermore, several unique residues to each type of interaction in the ligand 
affinity maps (Fig. 10F and G) can be further pursued and analyzed in details. Additionally, 
it would be of great interest to employ structure activity relationship (SAR) analyses to 
design derivatives of the top hits. This would assist in maximizing the efficacy of these 
compounds as would also validate anti-tumor efficacy in in vivo mouse cancer xenograft 
models. From a broader perspective, epigenetic enzymes are proving to be increasingly 
critical in a wide variety of diseases, and the approach described here can accelerate the 
development of important tools required for this purpose.
5. Conclusion
In summary, our study allows for rapid optimization of a robot-based automated AlphaLISA 
protocol that can be modified for other epigenetic targets of interest. Here, we described 
PRMT5 as a representative target and adapted the AlphaLISA screen to build a HTS screen 
platform to identify PRMT5 inhibitors. The adaptability and high throughput nature of this 
approach can be exploited to pursue a screening protocol for any enzymatic target of 
interest. Importantly, the two compounds that we identified, P1608K04 and P1618J22, are 
novel PRMT5 inhibitors that exhibited much higher efficacy than the commercial PRMT5 
inhibitor EPZ015666 in PDAC and CRC cells. These exciting studies can lead to the 
development of more effective therapeutic options targeting PRMT5 in PDAC and CRC. In a 
broader sense, the adapted AlphaLISA HTS approach we reported here may serve as a 
powerful tool for studying a wide variety of critical targets in cancers and other diseases.
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Fig. 1. Principle of AlphaLISA™ screen for quantifying PRMT5 methylation activity
Biotinylated histone H4 is incubated with PRMT5 and a methyl donor, S-adenosyl-l-
methionine (SAM). PRMT5 symmetrically dimethylates the third arginine (R3) on Biotin-
H4 to form dimethylated Biotin-H4R3 (Biotin-H4R3me2) peptide. This product will further 
bind to Acceptor beads specific to the methylation site (Biotin-H4R3me2). Streptavidin-
coated Donor beads will bind to the biotinylated substrate. Interaction between the Acceptor 
and Donor beads emits a chemiluminescent signal, which will be detected using an 
EnVision® reader. The methylation activity of PRMT5 is proportional to the intensity of the 
signal.
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Fig. 2. Optimization of the AlphaLISA protocol
(A) Alpha signal graph, showing that the Alpha signal increased with increased substrate 
(Biotin-unmeH4R3) concentrations (10–100nM). (B) Alpha signal graph, showing that 
increased concentrations of the methyl donor SAM (0.2–4000μM) led to bell-shaped 
distribution of Alpha signal strength. We observed an increase in the Alpha signal, with a 
peak at 100μM of SAM, followed by a subsequent decrease with further increased SAM 
concentrations.
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Fig. 3. Determination of Z’ factor for PRMT5-specific AlphaLISA assay
Scatter plot, representing the data points for the 384-well plate, with the red points 
indicating the “maximum signal” wells and the purple points representing the “background” 
wells. The solid lines at the center represent the average values and the dotted lines at the top 
and bottom represent the +/− 3 × SD (standard deviation) values for the respective groups. 
The S/B (signal vs. background) ratio was calculated to be ~8.3 and the Z’ factor was 
determined to be 0.7.
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Fig. 4. Plate design for the quenching experiment to identify false hits from the AlphaLISA 
screen top hits
The first two columns (white dots; grey background) do not contain any compound and act 
as positive control, signifying “maximum signal”. Columns 1–22 had Biotin-H4R3me2 
substrate (dimethylated Biotin-H4R3) added at a final concentration of 15nM in each well. 
The last two columns do not have the Biotin-H4R3me2, and act as the “negative control”. 
Acceptor and Donor beads were added to each well. No PRMT5 enzyme was included in 
this experiment. Compounds that exhibited quenching of the Alpha signal were “false hits” 
and not true PRMT5 inhibitors, thus were removed from further testing.
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Fig. 5. Identification of top hits P1608K04 and P1618J22
(A) Workflow for the stepwise procedure that eventually led to the shortlisting of two top 
PRMT5 inhibitors, P1608K04 and P1618J22, among ~10,000 compounds from small 
compound libraries. Each step represents the experimental approach and the number of 
compounds to start with. (B) Structures of the 2 top hits: P1608K04 (Left panel) and 
P1618J22 (Right panel).
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Fig. 6. Determination of IC50 for using AlphaLISA assay
(A) Calculation of IC50 of P1608K04 using AlphaLISA, showing concentration-dependent 
decrease of Alpha signal. The IC50was~1.5μM. (B) The IC50of P1618J22 was calculated to 
be 16.5μM, using the same protocol as (A). The data represent the means ± SD for three 
independent experiments.
Prabhu et al. Page 20
Mol Biosyst. Author manuscript; available in PMC 2018 November 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Prabhu et al. Page 21
Mol Biosyst. Author manuscript; available in PMC 2018 November 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 7. P1608K04 and P1618J22 are potent inhibitors for viability in PDAC and CRC cells
(A) MTT assay with the treatment of P1608K04 in both PDAC (PANC1, MiaPaCa2, and 
AsPC1) and CRC cells (HT29, HCT116, and DLD1), showing that cell viability 
dramatically decreased in the presence of increasing concentrations of P1608K04. (B) MTT 
assay with the treatment of P1618J22 in both PDAC and CRC. The data represent the means 
± SD for three independent experiments. (C) Table, summarizing the IC50 values for 
P1608K04 and P1618J22 in PDAC and CRC cells, respectively.
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Figure 8. P1608K04 and P1618J22 decreased methylation at R30 on the p65 subunit of NF-κB
Western blot analysis, (A) PANC1 and (B) HT29 cells were treated with P1608K04 (Left 
panels) or P1618J22 (Right panels) at their IC50values, respectively. Samples were probed 
with specific anti-p65-R30me2 antibody. Decreased p65-R30me2 levels were observed in 
the compounds treated groups as compared with the control (ctrl) groups that are without 
compounds treatment. β-actin was used as a loading control.
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Fig. 9. P1608K04 and P1618J22 inhibited NF-κB activation and its target gene expression in 
PDAC and CRC cells
NF-κB luciferase assay in (A) PANC1 and (B) HT29 cells, indicating that treatment with 
increasing concentrations of P1608K04 or P1618J22 respectively for 24h led to a 
corresponding decrease in NF-κB activation. The data represent the means ± SD for three 
independent experiments. *P < 0.05 vs. 0μM. (C) and (D) Quantitative PCR (qPCR) 
analysis, showing the expression of the typical NF-κB target genes, IL8 and TNFα, was 
decreased after the treatment of P1608K04 or P1618J22 respectively in PANC1 (C) and 
HT29 cells (D). The data represent the means ± SD for three independent experiments. *P < 
0.05 vs. 0μM.
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Fig. 10. In silico prediction of P1608K04 and P1618J22 binding to PRMT5. (A)–(D)
Binding poses predicted for P1608K04 and P1618J22. (A) and (C), in the presence or (B) 
and (D) in the absence of SAM, respectively. PRMT5 is shown in gray ribbons, while all 
ligands are shown in balls and sticks and colored with respect to atom type (0 atoms in red, 
N atoms in blue, S atoms in yellow. C atoms are colored in purple, orange, and cyan in 
SAM, EPZ015666, and the P1608O04 or P1618J22, respectively.) In panels (B) and (D), the 
position of SAM is depicted with a purple wireframe surface to indicate if the docked ligand 
overlaps. (E) Docking scores for the docking poses depicted in (A)-(D). (F) and (G) Ligand 
affinity maps, depicting the residues of PRMT5 that interact with P1608K04 (F) or 
P1618J22 (G) in the docking poses in (A)–(D).
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Fig. 11. Hypothetical model
Optimized AlphaLISA screen for PRMT5 inhibitors identified and confirmed P1608K04 
and P1618J22 as two top hits. This inhibitory effect could partly be via inhibiting PRMT5-
mediated NF-κB methylation and subsequent activation, resulting in decreased cancer 
associated target gene expression. This process would ultimately lead to the alleviation of 
cancer phenotype.
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Table 1
Protocol for High Throughput Screening for PRMT5 AlphaLISA Assay
Step Parameter Value Description
1 Dispense substrate & cofactor 10μl 2× mix of SAM/peptide
2 Dispense compounds 250nL 80× compound (1.25% (v/v) DMSO)
3 Dispense enzyme 10μl 2× PRMT5 enzyme
4 Incubation time 1h RT, sealed
5 AlphaLISA Acceptor beads 5μl 1:42 dilution of Acceptor beads mix
6 Incubation time 1h RT, sealed
7 AlphaLISA Donor beads 5μl 1:42 dilution of Donor beads mix
8 Incubation time 0.5h RT, sealed
9 Assay readout 615nm EnVision plate reader; Alphascreen mode
Step Notes
1. Final concentrations are 30nM Biotin-unmeH4R3, 100μM SAM prepared in MilliQ water.
2. Final compound concentration: 12.5μM; columns 21–24 do not have compound and have only DMSO/water with a final DMSO concentration at 
1.25%.
3. Columns 23 and 24 only has no enzyme, prepared in enzyme reaction buffer.
4. Plates sealed with adhesive film and covered with aluminum foil.
5. Final concentration is 20μg/ml for Acceptor beads mix, prepared in the dark using 1× Epigenetics buffer.
6. Plates sealed with adhesive film, covered with aluminum foil and kept in dark.
7. Final concentration is 20μg/ml for Donor beads mix, prepared in the dark using 1× Epigenetics buffer.
8. Plates sealed with adhesive film, covered with aluminum foil and kept in dark.
9. Alphascreen (570nm) emission filter
PRMT5, protein arginine methyltransferase 5; H4R3, arginine 3 of histone H4; SAM, S-adenosyl-l-methionine
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